You are here

Cancer Discov DOI:10.1158/2159-8290.CD-12-0012

Circumventing cancer drug resistance in the era of personalized medicine.

Publication TypeJournal Article
Year of Publication2012
AuthorsGarraway, LA, Jänne, PA
JournalCancer Discov
Volume2
Issue3
Pages214-26
Date Published2012 Mar
ISSN2159-8290
KeywordsAntineoplastic Agents, Drug Resistance, Neoplasm, Humans, Neoplasms, Precision Medicine
Abstract

UNLABELLED: All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s).

SIGNIFICANCE: Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways.

URLhttp://cancerdiscovery.aacrjournals.org/cgi/pmidlookup?view=long&pmid=22585993
DOI10.1158/2159-8290.CD-12-0012
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/22585993?dopt=Abstract

Alternate JournalCancer Discov
PubMed ID22585993
Grant ListR01 CA135257 / CA / NCI NIH HHS / United States
P50 CA090578 / CA / NCI NIH HHS / United States
R01CA135257 / CA / NCI NIH HHS / United States